Last edition
News about "gadoquatrane"
US FDA Approves Bayer's AMBELVIST for Contrast-Enhanced MRI
Bayer’s AMBELVIST (gadoquatrane) has received US FDA approval for contrast-enhanced MRI to detect and visualise lesions with abnormal vascularity in the Central Nervous System (CNS) and other body regions. The approval expands advanced imaging options with a next-generation gadolinium-based contrast agent for improved diagnostic evaluation.
Gadoquatrane | 15/06/2026 | By News Bureau
Bayer to Showcase Low-Dose MRI Contrast Innovation at ECR 2026
Bayer brings next-generation contrast agents and smart radiology solutions to ECR 2026, spotlighting progress in low-dose MRI imaging and clinical innovation.
Gadoquatrane | 28/01/2026 | By News Bureau | 435
US FDA Accepts Gadoquatrane for Review: Bayer
Bayer has submitted New Drug Application (NDA) for low dose contrast agent gadoquatrane to seek approval for contrast-enhanced Magnetic Resonance Imaging (MRI) of the Central Nervous System (CNS) and other body regions for adults and paediatric patients including neonates.
Gadoquatrane | 27/08/2025 | By Dineshwori | 269
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy